Live Chat
0 ITEMS0

0 ITEMS

৳
0
Dhaka

Selected City: Dhaka

Use my current Location


Change City

EN 

|

 বাং

Dhaka

Use my current Location


Change City

Selected City: Dhaka

Grocery
Pharmacy
Cookups
  • Offers
  • Egg Club
  • Daily Deals
  • Favourites
  • Common Conditions 
  • Sexual Wellness
  • Birth Control Contraceptives
  • Vitamins & Supplements 
  • Medical Devices
  • Medical Accessories
  • Personal Care 
  • Health & Wellness 
  • Baby Care 
  • Premium Care
  • Food Aid
  • Recipes
Help
File a complaint

    Adempa Tablet 10mg

    10 tablets
    ৳250
    0
    in bag

    Product Information

    ADEMPA

    Presentation

    Adempa 10 : Pale yellow, round shaped film coated tablet; each tablet contains Empagliflozin INN10 mg.

    Adempa 25 : Pale yellow, oval shaped film coated tablet; each tablet contains Empagliflozin INN 25 mg.

    Indications

    Empagliflozin is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to

    diet and exercise.

    – as monotherapy when metformin is considered inappropriate due to intolerance and

    – in addition to other medicinal products for the treatment of diabetes.

    Dose and administration

    The recommended starting dose is 10 mg Empagliflozin once daily for monotherapy and add-on combination therapy with other

    medicinal products for the treatment of diabetes. In patients tolerating Empagliflozin 10 mg once daily who have an eGFR =60

    ml/min/1.73 m2 and need tighter glycaemic control, the dose can be increased to 25 mg once daily. The maximum daily dose is 25 mg

    . When Empagliflozin is used in combination with a sulphonylurea or with insulin, a lower dose of the sulphonylurea or insulin may

    be considered to reduce the risk of hypoglycaemia.

    Renal impairment: Due to the mechanism of action, the glycaemic efficacy of Empagliflozin is dependent on renal function. No dose

    adjustment is required for patients with an eGFR =60 ml/min/1.73 m2 or CrCl =60 ml/min. Empagliflozin should not be initiated in

    patients with an eGFR <60 ml/min/1.73 m2 or CrCl <60 ml/min. In patients tolerating Empagliflozin whose eGFR falls persistently

    below 60 ml/min/1.73 m2 or CrCl below 60 ml/min, the dose of Empagliflozin should be adjusted to or maintained at 10 mg once

    daily. Empagliflozin should be discontinued when eGFR is persistently below 45 ml/min/1.73 m2 or CrCl persistently below 45

    ml/min. Empagliflozin should not be used in patients with end stage renal disease (ESRD) or in patients on dialysis as it is not

    expected to be effective in these patients. Hepatic impairment: No dose adjustment is required for patients with hepatic

    impairment. Empagliflozin exposure is increased in patients with severe hepatic impairment. Therapeutic experience in patients

    with severe hepatic impairment is limited and therefore not recommended for use in this population . Elderly: No dose adjustment

    is recommended based on age. In patients 75 years and older, an increased risk for volume depletion should be taken into account.

    In patients aged 85 years and older, initiation of Empagliflozin therapy is not recommended due to the limited therapeutic

    experience. Paediatric population: The safety and efficacy of Empagliflozin in children and adolescents has not yet been

    established. No data are available. The tablets can be taken with or without food, swallowed whole with water. If a dose is

    missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.

    Contra-indications, Warning etc. Hypersensitivity to the active substance or to any of the excipients. Diabetic ketoacidosis: Rare

    cases of diabetic ketoacidosis (DKA), including life-threatening and fatal cases, have been reported in patients treated with

    SGLT2 inhibitors, including empagliflozin. The risk of diabetic ketoacidosis must be considered in the event of non-specific

    symptoms such as nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or

    sleepiness. Patients should be assessed for ketoacidosis immediately if these symptoms occur, regardless of blood glucose level.

    In patients where DKA is suspected or diagnosed, treatment with empagliflozin should be discontinued immediately. Treatment should

    be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses. In both cases,

    treatment with empagliflozin may be restarted once the patient's condition has stabilised. Before initiating empagliflozin,

    factors in the patient history that may predispose to ketoacidosis should be considered. The safety and efficacy of empagliflozin

    in patients with type 1 diabetes have not been established and empagliflozin should not be used for treatment of patients with

    type 1 diabetes. Limited data from clinical trials suggest that DKA occurs with common frequency when patients with type 1

    diabetes are treated with SGLT2 inhibitors. Renal impairment: In patients tolerating Empagliflozin whose eGFR falls persistently

    below 60 ml/min/1.73 m2 or CrCl below 60 ml/min, the dose of Empagliflozin should be adjusted to or maintained at 10 mg once

    daily. Empagliflozin should be discontinued when eGFR is persistently below 45 ml/min/1.73 m2 or CrCl persistently below 45

    ml/min. Empagliflozin should not be used in patients with end stage renal disease (ESRD) or in patients on dialysis as it is not

    expected to be effective in these patients. Monitoring of renal function: Due to the mechanism of action, the glycaemic efficacy

    of empagliflozin is dependent on renal function. Therefore assessment of renal function is recommended as follows: - Prior to

    empagliflozin initiation and periodically during treatment, i.e. at least yearly. - Prior to initiation of any concomitant

    medicinal product that may have a negative impact on renal function. Hepatic Injury: Cases of hepatic injury have been reported

    with empagliflozin in clinical trials. A causal relationship between empagliflozin and hepatic injury has not been established.

    Elevated haematocrit: Haematocrit increase was observed with empagliflozin treatment. Elderly: No dose adjustment is recommended

    based on age. In patients 75 years and older, an increased risk for volume depletion should be taken into account. In patients

    aged 85 years and older, initiation of Empagliflozin therapy is not recommended due to the limited therapeutic experience.

    Therefore, special attention should be given to their volume intake in case of co-administered medicinal products which may lead

    to volume depletion (e.g. diuretics, ACE-inhibitors). Risk for volume depletion: Based on the mode of action of SGLT-2 inhibitors,

    osmotic diuresis accompanying therapeutic glucosuria may lead to a modest decrease in blood pressure. Therefore, caution should be

    exercised in patients for whom an empagliflozin-induced drop in blood pressure could pose a risk, such as patients with known

    cardiovascular disease, patients on anti-hypertensive therapy with a history of hypotension or patients aged 75 years and older.

    Urinary tract infections: Post-marketing cases of complicated urinary tract infections including pyelonephritis and urosepsis have

    been reported in patients treated with empagliflozin. Temporary interruption of empagliflozin should be considered in patients

    with complicated urinary tract infections. Drug Interaction: Diuretics. Empagliflozin may add to the diuretic effect of thiazide

    and loop diuretics and may increase the risk of dehydration and hypotension. Insulin and insulin secretagogues: Insulin and

    insulin secretagogues, such as sulphonylureas, may increase the risk of hypoglycaemia. Therefore, a lower dose of insulin or an

    insulin secretagogue may be required to reduce the risk of hypoglycaemia when used in combination with empagliflozin. Effects of

    Empagliflozin on other medicinal products: Interaction studies conducted in healthy volunteers suggest that Empagliflozin had no

    clinically relevant effect on the pharmacokinetics of metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, simvastatin,

    warfarin, ramipril, digoxin, diuretics and oral contraceptives. Use in Pregnancy and lactation: As a precautionary measure, it is

    preferable to avoid the use of Empagliflozin during pregnancy.No data in humans are available on excretion of Empagliflozin into

    milk. Empagliflozin should not be used during breast-feeding. Empagliflozin has minor influence on the ability to drive and use

    machines. Patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines. Pharmaceutical

    Precaution Store in a cool and dry place, protected from light. Packaging quantities Adempa 10 : Carton containing 10 tablets in

    Alu-Alu blister. Adempa 25 : Carton containing 10 tablets in Alu-Alu blister. Manufactured by UniMed UniHealth Pharmaceuticals

    Limited B K Bari, Gazipur, Bangladesh ® Registered Trademark

    • 30 minute delivery
    • Cash on delivery
    • Pay with

    Chaldal logo

    Chaldal.com is an online shop available in Dhaka, Chattogram, Jashore, Khulna and Narayanganj. We believe time is valuable to our fellow residents, and that they should not have to waste hours in traffic, brave bad weather and wait in line just to buy basic necessities like eggs! This is why Chaldal delivers everything you need right at your door-step and at no additional cost.

    Customer Service

    • Contact Us
    • FAQ

    About Chaldal

    • Privacy Policy
    • Terms of Use

    For Business

    • Corporate
    16710
    or email[email protected]